News Sentiment

QURE sentiment intelligence

Uniqure NV news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 62 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 46.29 Week of 19 Jun 2026
Weighted tone 57/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

78/100 classification confidence.

Company focus 55

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

+67.9% over one week, +91.4% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

uniQure (QURE) CEO sells 206,100 shares and exercises stock options

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 78/100 classification
One-week reaction 67.9% Price confirming higher
Trend fit Trend active 91.4% over four weeks
Fair value 226.5% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 20
Neutral 35
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 55
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 19
Market source 9
simplywall.st 4
Stocktwits 3
Investing.com 3
TradingView 2
GlobeNewswire 2
Moomoo 2

Event Lens

What the news is about

Classified themes
Market update 32
Earnings 14
Regulatory and legal 10
Analyst action 4
Guidance 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 62
Stock Titan Direct company coverage

FDA says 3-year trial data can support Huntington’s treatment filing

uniQure announced that the FDA has indicated its ~3-year Phase I/II study data for AMT-130 in Huntington's disease can serve as the primary basis for a Biologics License Application (BLA) for accelerated approval. The company plans to submit the BLA in Q3 2026 and will work with

Tone
Positive 74/100
Event
Regulatory and legal
Published
17 Jun 2026 11:09
Source
Stock Titan
GlobeNewswire Direct company coverage

uniQure Announces Plan for BLA Submission for AMT-130 in Huntington’s Disease

uniQure plans to submit a Biologics License Application (BLA) for accelerated approval of AMT-130 for Huntington's disease to the FDA in the third quarter of 2026. The FDA has agreed that the 3-year analysis from the Phase I/II study can serve as the primary basis for this BLA, c

Tone
Positive 71/100
Event
Earnings
Published
17 Jun 2026 07:05
Source
GlobeNewswire
Stock Titan Direct company coverage

uniQure (QURE) investors approve share plan, charter and board at 2026 AGM

uniQure N.V. shareholders approved all proposals at their 2026 annual general meeting, including amendments to the 2014 Share Incentive Plan to increase shares for equity compensation and modifications to the Articles of Association to reflect Dutch large company regime and incre

Tone
Positive 65/100
Event
Market update
Published
15 Jun 2026 20:09
Source
Stock Titan
Simply Wall Street Direct company coverage

Don't Ignore The Insider Selling In uniQure

uniQure's Chief Customer & Strategy Officer, Kylie O'Keefe, recently sold US$431k worth of stock, representing 13% of their holding. This was the largest insider sale in the past year, and no insider buying has been observed in the same period. While insider ownership is not part

Tone
Negative 30/100
Event
Market update
Published
15 Jun 2026 10:09
Source
Simply Wall Street
Stocktwits Direct company coverage

Why Did QURE Stock Almost Halve Pre-Market Today?

uniQure (QURE) stock dropped nearly 45% pre-market after the FDA indicated that Phase I/II data for its Huntington’s disease gene therapy, AMT-130, are insufficient for a marketing application. The FDA recommended a prospective, randomized, double-blind, sham-surgery-controlled s

Tone
Negative 8/100
Event
Market update
Published
13 Jun 2026 21:40
Source
Stocktwits
Stock Titan Direct company coverage

uniQure (QURE) director Leonard Post awarded RSUs, options and sells shares for taxes

uniQure (QURE) director Leonard E. Post recently received equity compensation including 7,550 restricted share units and 13,980 stock options. He subsequently sold 1,993 Ordinary Shares at a weighted average price of $27.06, solely to cover estimated withholding taxes related to

Tone
Neutral 50/100
Event
Market update
Published
13 Jun 2026 10:09
Source
Stock Titan
Stock Titan Direct company coverage

uniQure (QURE) director receives RSUs, stock options and sells shares for taxes

uniQure N.V. director Jeremy P. Springhorn reported receiving 7,550 restricted share units and 13,980 stock options on June 10, 2026, both vesting after one year. On June 11, 2026, he sold 1,993 Ordinary Shares at a weighted average price of $27.06 solely to cover withholding tax

Tone
Neutral 50/100
Event
Market update
Published
13 Jun 2026 09:40
Source
Stock Titan
Stock Titan Direct company coverage

Tax-related share sale by uniQure (NASDAQ: QURE) chief customer officer

uniQure N.V.'s Chief Customer & Strategy Officer, Kylie O’Keefe, sold 15,936 ordinary shares on June 11, 2026, at a weighted average price of $27.06 per share. This sale was a non-discretionary transaction, executed automatically upon the vesting of restricted share units to cove

Tone
Neutral 50/100
Event
Market update
Published
13 Jun 2026 09:40
Source
Stock Titan
Stock Titan Direct company coverage

RSU grant, options and tax sale for uniQure (NASDAQ: QURE) director

uniQure N.V. director David D. Meek received 7,550 restricted share units and stock options for 13,980 Ordinary Shares. Concurrent with this, 1,993 Ordinary Shares were sold at a weighted average price of $27.06, solely to cover estimated withholding taxes upon RSU vesting, a non

Tone
Neutral 50/100
Event
Market update
Published
12 Jun 2026 22:09
Source
Stock Titan
Stock Titan Direct company coverage

Director Jack Kaye at uniQure (QURE) gets RSUs and options, sells shares for taxes

uniQure (QURE) director Jack Kaye received 7,550 restricted share units (RSUs) and options for 13,980 Ordinary Shares. Following the RSU vesting, 1,993 shares were sold to cover tax obligations, not as a discretionary trade. Kaye directly holds 25,996 Ordinary Shares after these

Tone
Neutral 50/100
Event
Market update
Published
12 Jun 2026 21:09
Source
Stock Titan